Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…
Seronegative RA May Be on the Rise
A study comparing trends in the incidence of RA from 2005 to 2014 with previous decades showed a shift in RA subset, suggesting the need for timely recognition of rheumatoid factor-negative RA…
Clinical Criteria for RA & Early Non-Response to Certolizumab as Predictors of Patient Outcomes
A recent study compared three clinical criteria for rheumatoid arthritis (RA) in patients using certolizumab, assessing the predictability of treatment non-response. Researchers found Clinical Disease Activity Index measurement at three months may predict patient outcomes at 12 months…
Precision Medicine Today: Predicting Treatment Response in Patient Subgroups
SNOWMASS VILLAGE, COLO.—Choosing the right treatment at the right time is the brass ring all rheumatologists hope for. Precision medicine provides the ability to leverage clinical, biomarker and omics data to predict and personalize future treatment for rheumatoid arthritis (RA). “New data and new methods to analyze the data are helping us better predict patterns…
Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same
SNOWMASS VILLAGE, COLO.—Current trends in rheumatoid arthritis (RA) therapy are the increased use of newer medication categories, such as Janus kinase (JAK) inhibitors (Jakinibs) and biologics, and the rising costs of treatment. Unchanged is the consistent use of methotrexate as an effective therapy. These topics and more were discussed at the ACR Winter Symposium during…
Researchers Give Update on Janus Kinase (JAK) Inhibitors
SNOWMASS VILLAGE, COLO.—Janus kinase inhibitors—or Jakinibs—are a relatively new class of disease-modifying anti-rheumatic drugs (DMARDs) that perform well and have a safety profile comparable to biologics. This group of drugs was the subject of The New Frontier: Comparative Safety of JAK Inhibitors, a presentation given at the ACR Winter Symposium by Kevin L. Winthrop, MD,…
Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap
Clinically amyotrophic dermatomyositis (CADM), a subset of dermatomyositis (DM), is a rare autoimmune disease characterized by typical DM cutaneous findings (e.g., heliotrope rash, Gottron papules, Gottron sign) without evidence of myositis.1 The incidence of DM and CADM is approximately 9.63 per 1 million people and 2.08 per 1 million people, respectively.2 The association with development…
Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis
Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections. Triple Therapy One study, in Arthritis Care & Research, found the risk of…
Local Depletion of Resident Memory T Cells May Reduce Site-Specific Joint Flares
A study found resident memory T cells may mediate inflammatory arthritis and trigger flares in specific joints, suggesting local depletion of these cells could be a therapeutic strategy…
Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib
(Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests. Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 74
- Next Page »